1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

In development [GID-TA11570] Expected publication date: 30 April 2025

  • Project information
  • Project documents

NICE is considering whether new evidence has emerged that would affect the recommendation of TA909.


  • Review proposal paper MSWord 40 KB 25 June 2024  
  • Stakeholder matrix MSWord 28 KB 25 June 2024